期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms22010199
关键词
liver cirrhosis; liver fibrosis; gut microbiome; gut-liver axis
资金
- Hallym University Research Fund
- Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [NRF-2018M3A9F3020956, NRF-2019R1I1A3A01060447, NRF2020R1I1A3073530, NRF-2020R1A6A1A03043026]
Liver cirrhosis is a common chronic liver disease worldwide with various causes, and there is still no clear consensus on its treatment. Recent studies have shown that modulating the gut microbiome with probiotics can ameliorate the progression of liver disease, indicating a potential new treatment approach for cirrhosis.
Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing cholangitis and Wilson's disease can also lead to cirrhosis. Moreover, alcohol can cause cirrhosis on its own and exacerbate chronic liver disease of other causes. The treatment of cirrhosis can be divided into addressing the cause of cirrhosis and reversing liver fibrosis. To this date, there is still no clear consensus on the treatment of cirrhosis. Recently, there has been a lot of interest in potential treatments that modulate the gut microbiota and gut-liver axis for the treatment of cirrhosis. According to recent studies, modulation of the gut microbiome by probiotics ameliorates the progression of liver disease. The precise mechanism for relieving cirrhosis via gut microbial modulation has not been identified. This paper summarizes the role and effects of the gut microbiome in cirrhosis based on experimental and clinical studies on absorbable antibiotics, probiotics, prebiotics, and synbiotics. Moreover, it provides evidence of a relationship between the gut microbiome and liver fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据